1. Detection of antibody to the PreS2 sequence of the hepatitis B virus envelope protein using an immuno-ligand assay with a silicon sensor detection system.
- Author
-
Hurni WM, Miller WJ, Zuk RF, and Kung VT
- Subjects
- Antibodies, Monoclonal immunology, Biotin chemistry, Dose-Response Relationship, Immunologic, Fluorescein, Fluoresceins chemistry, Humans, Ligands, Radioimmunoassay, Silicon, Vaccines, Synthetic immunology, Hepatitis B Antibodies analysis, Hepatitis B Surface Antigens immunology, Immunoassay methods, Protein Precursors immunology
- Abstract
Sensitive immunoassays are essential for establishing the efficacy of recombinant vaccines to hepatitis B virus (HBV). These experimental vaccines include the PreS2 and S domains of the HBV envelope protein. To facilitate measurement of antibody against HBV PreS2, we employed the immuno-ligand assay with silicon sensor-based detection. Labeling of immune reagents with the haptens biotin and fluorescein allows adaptation to the immunofiltration light addressable potentiometric sensor (LAPS) system. A biotinylated monoclonal anti-PreS2 antibody and anti-PreS2 in clinical serum samples competitively bind in liquid phase to a fluorescein labeled PreS2 + S antigen. Streptavidin mediates the immobilization on biotinylated nitrocellulose membranes. Fluorescein mediates binding of an anti-fluorescein urease conjugate to the immune complex. Urease serves as the signal-generating component which subsequently is measured in the LAPS reader. In comparison to a competitive RIA, the immuno-ligand assay demonstrated a four-fold improved sensitivity using a smaller sample volume. The higher sensitivity resulted in earlier detection of seroconversion during a clinical vaccine study.
- Published
- 1991
- Full Text
- View/download PDF